Log in

NASDAQ:IDXG - Interpace Diagnostics Group Stock Price, Forecast & News

+0.44 (+5.26 %)
(As of 02/18/2020 06:00 AM ET)
Today's Range
Now: $8.80
50-Day Range
MA: $5.63
52-Week Range
Now: $8.80
Volume63,506 shs
Average Volume56,598 shs
Market Capitalization$33.62 million
P/E RatioN/A
Dividend YieldN/A
Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Services
Current SymbolNASDAQ:IDXG



Sales & Book Value

Annual Sales$21.90 million
Book Value$11.48 per share


Net Income$-12,190,000.00


Market Cap$33.62 million
Next Earnings Date3/17/2020 (Estimated)
OptionableNot Optionable

Receive IDXG News and Ratings via Email

Sign-up to receive the latest news and ratings for IDXG and its competitors with MarketBeat's FREE daily newsletter.

Interpace Diagnostics Group (NASDAQ:IDXG) Frequently Asked Questions

What is Interpace Diagnostics Group's stock symbol?

Interpace Diagnostics Group trades on the NASDAQ under the ticker symbol "IDXG."

How were Interpace Diagnostics Group's earnings last quarter?

Interpace Diagnostics Group Inc (NASDAQ:IDXG) released its earnings results on Wednesday, November, 13th. The business services provider reported ($0.19) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.19) by $0.00. The business services provider earned $7.73 million during the quarter, compared to the consensus estimate of $10 million. Interpace Diagnostics Group had a negative return on equity of 58.48% and a negative net margin of 77.55%. View Interpace Diagnostics Group's Earnings History.

When is Interpace Diagnostics Group's next earnings date?

Interpace Diagnostics Group is scheduled to release their next quarterly earnings announcement on Tuesday, March 17th 2020. View Earnings Estimates for Interpace Diagnostics Group.

What guidance has Interpace Diagnostics Group issued on next quarter's earnings?

Interpace Diagnostics Group issued an update on its FY 2020 After-Hours earnings guidance on Monday, November, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $$50-50 million, compared to the consensus revenue estimate of $$52.44 million.

What price target have analysts set for IDXG?

3 equities research analysts have issued 12 month target prices for Interpace Diagnostics Group's stock. Their forecasts range from $2.00 to $15.00. On average, they anticipate Interpace Diagnostics Group's share price to reach $6.67 in the next year. This suggests that the stock has a possible downside of 24.2%. View Analyst Price Targets for Interpace Diagnostics Group.

What is the consensus analysts' recommendation for Interpace Diagnostics Group?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Interpace Diagnostics Group in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Interpace Diagnostics Group.

What are Wall Street analysts saying about Interpace Diagnostics Group stock?

Here are some recent quotes from research analysts about Interpace Diagnostics Group stock:
  • 1. Maxim Group analysts commented, "Interpace Diagnostics reported 4Q18 and FY18 net revenue of $5.8M, up 33% y/y, and $21.9M, up 38% y/y, respectively, due to expansion in units and improved reimbursement. Net loss was ($4.0M) for the quarter and ($12.2M) for the year. The company ended the period with $6.1M in cash, not including $6.1M in net proceeds from a January 2019 equity financing. Interpace also has a $4M credit facility in place." (3/20/2019)
  • 2. HC Wainwright analysts commented, "Our 12-month price target is derived from an estimated market value of the firm at $120M. This includes a discounted cash flow analysis based asset value for the company’s three commercialized laboratory-developed tests (LDTs), with a 15% discount rate and a 2% terminal growth rate, and assuming 39M shares outstanding at the end of 2019." (2/20/2019)

Has Interpace Diagnostics Group been receiving favorable news coverage?

News stories about IDXG stock have trended very negative on Tuesday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Interpace Diagnostics Group earned a coverage optimism score of -3.0 on InfoTrie's scale. They also assigned news stories about the business services provider a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Interpace Diagnostics Group.

Are investors shorting Interpace Diagnostics Group?

Interpace Diagnostics Group saw a drop in short interest in January. As of January 31st, there was short interest totalling 137,700 shares, a drop of 90.8% from the January 15th total of 1,500,000 shares. Based on an average daily volume of 51,200 shares, the short-interest ratio is currently 2.7 days. Currently, 4.3% of the company's shares are sold short. View Interpace Diagnostics Group's Current Options Chain.

Who are some of Interpace Diagnostics Group's key competitors?

What other stocks do shareholders of Interpace Diagnostics Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Interpace Diagnostics Group investors own include Histogenics (HSGX), Novavax (NVAX), AVEO Pharmaceuticals (AVEO), Magnegas Applied Tchnlgy Sltns (MNGA), SCYNEXIS (SCYX), Advanced Micro Devices (AMD), Genocea Biosciences (GNCA), Trevena (TRVN), Netflix (NFLX) and Verastem (VSTM).

Who are Interpace Diagnostics Group's key executives?

Interpace Diagnostics Group's management team includes the folowing people:
  • Mr. Jack E. Stover, CEO, Pres & Director (Age 66)
  • Mr. James E. Early, CFO, Sec. & Treasurer (Age 65)
  • Mr. Gregory Richard, Sr. VP & Chief Commercial Officer (Age 52)
  • Mr. Glenn Gershon, Sr. VP of Operations
  • Mr. Thomas John Freeburg, Chief Accounting Officer (Age 51)

Who are Interpace Diagnostics Group's major shareholders?

Interpace Diagnostics Group's stock is owned by a number of of retail and institutional investors. Top institutional investors include Perkins Capital Management Inc. (60.10%), Essex Investment Management Co. LLC (17.52%), Virtu Financial LLC (2.26%), Cambridge Investment Research Advisors Inc. (1.44%) and UBS Group AG (0.48%). View Institutional Ownership Trends for Interpace Diagnostics Group.

Which major investors are selling Interpace Diagnostics Group stock?

IDXG stock was sold by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc.. View Insider Buying and Selling for Interpace Diagnostics Group.

Which major investors are buying Interpace Diagnostics Group stock?

IDXG stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC, Essex Investment Management Co. LLC, UBS Group AG and Cambridge Investment Research Advisors Inc.. View Insider Buying and Selling for Interpace Diagnostics Group.

How do I buy shares of Interpace Diagnostics Group?

Shares of IDXG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Interpace Diagnostics Group's stock price today?

One share of IDXG stock can currently be purchased for approximately $8.80.

How big of a company is Interpace Diagnostics Group?

Interpace Diagnostics Group has a market capitalization of $33.62 million and generates $21.90 million in revenue each year. The business services provider earns $-12,190,000.00 in net income (profit) each year or ($4.30) on an earnings per share basis. Interpace Diagnostics Group employs 89 workers across the globe.View Additional Information About Interpace Diagnostics Group.

What is Interpace Diagnostics Group's official website?

The official website for Interpace Diagnostics Group is http://www.interpacediagnostics.com/.

How can I contact Interpace Diagnostics Group?

Interpace Diagnostics Group's mailing address is MORRIS CORPORATE CENTER 1 BUILDING C 300 INTERPACE PARKWAY, PARSIPPANY NJ, 07054. The business services provider can be reached via phone at 855-776-6419 or via email at [email protected]

MarketBeat Community Rating for Interpace Diagnostics Group (NASDAQ IDXG)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  277 (Vote Outperform)
Underperform Votes:  202 (Vote Underperform)
Total Votes:  479
MarketBeat's community ratings are surveys of what our community members think about Interpace Diagnostics Group and other stocks. Vote "Outperform" if you believe IDXG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDXG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2020 by MarketBeat.com Staff

Featured Article: What is the Rule of 72?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel